A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

Under the agreement, Mankind Pharma will have the exclusive rights to register, import, market, sell, and distribute Sintilimab in India. Credit: Piotr Swat/Shutterstock. Mankind Pharma has entered ...

AST-006 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase I for Breast Cancer.

KGYY-15 is under clinical development by Op-T-Mune and currently in Phase I for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase I drugs for Type 1 Diabetes (Juvenile Diabetes) have ...

Gene Therapy to Target GD2 for Oncology is under clinical development by Bristol-Myers Squibb and currently in Phase I for Osteosarcoma.

CTEcells is under clinical development by CTE Biologics and currently in Phase II for Chronic Traumatic Encephalopathy (CTE).

Tricaprilin is under clinical development by Cerecin and currently in Phase II for Infantile Spasm (West Syndrome).

Trientine hydrochloride is under clinical development by Innolife and currently in Phase II for Systolic Heart Failure.

AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company. It is engaged in the discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related ...

Darigabat is under clinical development by Cerevel Therapeutics and currently in Phase II for Seizures. According to GlobalData, Phase II drugs for Seizures have an 82% phase transition success rate ...